ArticleEye (London, England)2025
PRESERFLO™ MicroShunt as a treatment option for highly increased intraocular pressure in primary open angle glaucoma and pseudoexfoliation glaucoma.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Factors Associated with Favorable One-Year Outcomes After PreserFlo MicroShunt Implantation: Insights from Anterior Segment Optical Coherence Tomography.Advances in therapy · 2026Article
- A-stream glaucoma shunt versus trabeculectomy: 1-year results on efficacy and safety.Scientific reports · 2026Article
- One-Year Outcome of PreserFlo MicroShunt Implantation in Patients with Open Angle Glaucoma: Real-World Data from a Tertiary Centre.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Preserflo MicroShunt Outcomes in Rare and Refractory Glaucoma Entities Compared with Matched Primary Open-Angle Glaucoma Controls: A Retrospective Exploratory Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Novel Dual-Device Strategy: Failed PRESERFLO MicroShunt Connected to an Ahmed ClearPath - Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Preserflo-MicroShunt (PF) is an established device for treating glaucoma, effectively reducing intraocular pressure (IOP) with a good safety record. However, its efficacy in eyes with significantly elevated preoperative IOP levels is not well-documented due to exclusion from many clinical studies. This study aims to evaluate PF outcomes in eyes with highly increased IOP and compare them with those having moderately increased levels.
methodsRetrospectively, eyes diagnosed with primary open angle glaucoma (POAG) or pseudoexfoliation glaucoma (PXG) undergoing PF were analysed. They were categorized into two groups: highly increased IOP (HI-IOP, ≥30 mmHg) and moderately increased IOP (MI-IOP, ≤25 mmHg). IOP, number of IOP lowering medications (NoM), success rates (SR), and postoperative complications were compared at 1, 3, 6, and 12 months.
resultsOne year postoperatively, IOP was reduced from 39.0 ± 7.4 mmHg to 14.4 ± 4.4 mmHg in the HI-IOP and from 19.5 ± 3.6 mmHg to 14.0 ± 4.5 mmHg in the MI-IOP group. NoM decreased significantly in both groups (p < 0.001 for all). Success rates did not differ between groups during the first year (p > 0.05 in all subgroups). However, the HI- IOP group had higher rates of persistent hypotony (7% vs. 0%, p = 0.02) and tendentially higher rates of choroidal detachment (23% vs. 11%, p = 0.08). Other adverse events were rare and comparable. Further glaucoma surgery was required in 26% and 19% of cases, respectively (p = 0.41).
conclusionPF appears to be a suitable option for managing both highly and moderately increased IOP levels in POAG and PXG eyes, with comparable outcomes up to 12 months following surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.